Anaxsys Technology Ltd have been awarded funding up to £99,909 for Phase one of the SBRI East 2009 Innovation Competition.
read moreAnaxsys Technology is pleased to announce that it has completed the first closing of its current funding round raising £1.25m.
read moreThe Euroanaesthesia Conference and Trade Exhibition in Milan, Italy was attended by Anaxsys Technology. We received positive feedback on our survey at this event.
read moreAnaxsys Technology is pleased to announce that that an offer of grant to cover key intellectual property protection has been received from Advantage Proof of Concept Grant Fund.
read moreAnaxsys Technology announced today that a grant from the South East England Development Agency has been received for the development of the Asthma Alert device.
read moreOn 19 August 2008 a collaboration agreement was signed with Integrated Technologies Ltd (ITL).
read moreNews from Anaxsys Technology
Anaxsys Technology Ltd have been awarded funding up to £99909 for Phase one of the SBRI East 2009 Innovation Competition.
Anaxsys Technology is pleased to announce that it has completed the first closing of its current funding round raising £1.25m. This is £0.15m in excess of the minimum amount required to close the round. There is a second closing date of 31 October. The target is to raise a further £0.5m on the same terms as the first closing. The purpose of the extra funds is to provide head room for our business plan and provide resource for the development of our second product.
Dr Deryk Williams stated “we are extremely pleased that we have completed the first phase of our funding round. We welcome our new investors from the London Business Angels and the OION angel networks. These funds will allow us to develop our lead product, the Respiratory Rate Monitor, conduct clinical trials and apply for CE mark in Europe. We are confident that our leading edge technology will give us a significant advantage in the respiratory market since our respiratory products measure breath directly, continuously and require only tidal breathing.” For further information please contact Dr Deryk Williams, deryk@anaxsys.co.uk.
The Euroanaesthesia Conference and Trade Exhibition in Milan, Italy was attended by Anaxsys Technology. We received positive feedback on our survey at this event. Download the ESA 2009 Survey results here
Anaxsys Technology is pleased to announce that that an offer of grant to cover key intellectual property protection has been received from Advantage Proof of Concept Grant Fund.
Anaxsys Technology announced today that a grant from the South East England Development Agency has been received for the development of the Asthma Alert device.
On 19 August 2008 a collaboration agreement was signed with Integrated Technologies Ltd (ITL). The Technology Strategy Board (TSB) has accepted ITL as our partner and the project formally started on 1 September.
Anaxsys Technology has appointed Dr Bill Mason as Non-Executive Chairman. Dr Deryk Williams stated that we are delighted to have Bill join our board. His experience will be invaluable in helping us to implement our business strategy and he will add considerable value as our business develops.
Anaxsys Technology has announced that an offer letter of a grant from the Technology Strategy Board has been received. Dr Mark Payton, board member and principle at Mercia Technology Seed Fund stated this news is a testament to the quality of the products and concepts under development at Anaxsys.
Anaxsys Technology has appointed Team Consulting Ltd. of Cambridge to assist in the commercial design and development of key products in their development portfolio. Barbara Lead stated that “the involvement of Team Consulting will enable us to accelerate our development programmes and to ensure that our products are designed to maximise benefits to patients and provide a smooth transfer to manufacturing”.
Team Consulting are leading product development consultants to the pharmaceutical and life science industries, blending design and engineering with creativity and rigour to guide products safely through every stage of development with minimum risk.
Anaxsys Technology has appointed AARQ to provide regulatory support to the development programmes. Barbara Lead stated that it is essential that our development programmes meet EU and FDA requirements and the involvement of AARQ at this time will ensure that good quality regulatory submissions can be made in a timely manner.
Anaxsys Technology has agreed to expand their facilities at Keele University Science Park. Barbara Lead stated that this expansion is essential for us to meet our programme requirements and we are extremely pleased with the support that we have been provided with by the science park.
Anaxsys Technology announced today that Barbara Lead has joined the company as Commercial and Development Director. Dr Williams stated that Barbara has many years experience in the development and marketing of drug delivery systems for asthma and we believe that her expertise will enable Anaxsys to meet our development milestones in a timely manner. Her experience in marketing in the asthma area will enable us ensure that our products are developed with significant advantages over the competition.
Anaxsys Technology have moved to new offices in Tannery Lane, Send, Nr Woking. You will find our contact details here.
Anaxsys Technology opens a research laboratory at Keele University Science Park. Jason Gould of South East Growth Fund, a significant investor in Anaxsys Technology since May 2004, said “we are pleased to have this facility at this superb centre which can be expanded as our development programme gathers pace”.
Anaxsys Technology raises second round funds of £1.6m from VC investors and Business Angels.
Dr Deryk Williams stated “we are extremely pleased that we have completed our funding round for a substantial sum. These funds will allow us to develop our lead product to CE mark in Europe and allow us to start clinical studies in USA. We are confident that our leading edge technology will give us a significant advantage in the respiratory market since our asthma and COPD diagnostic and disease management systems require only tidal breathing.
In our proof of concept asthma diagnostic clinical study patients and the investigator Professor Martyn Partridge appreciated the simplicity and ease of use device and patients reported a preference for our device over spirometry”.
Anaxsys Technology (formerly Asthma Alert) was awarded £75,000 as a research grant from SEEDA.
Anaxsys Technology (formerly Asthma Alert) presented the results of the proof of concept clinical study in the diagnosis of asthma and COPD at British Thoracic Society Meeting.